Affecting around 165 million people worldwide, rheumatoid arthritis (RA) is a chronic, immune-related disease causing inflammation in the joints that can lead to severe pain, swelling and stiffness. RA can be life-altering, as progressive erosion of the joints over time can hinder everyday activities and in some cases lead to long-term disability.
You are here
Collaboration with Modern Biosciences to advance the development of novel compounds for RA
Janssen Affiliate Cilag GmbH International Acquires Covagen AG
Today, Cilag GmbH International, an affiliate of Janssen Pharmaceutical Companies of Johnson & Johnson, announced the acquisition of Covagen AG, a privately-held biopharmaceutical company specializing in the development of multispecific protein therapeutics. The acquisition strengthens Janssen’s Immunology portfolio through the addition of COVA322, a Phase 1b clinical candidate, and the company’s biotechnology capabilities through the addition of the FynomAb® Technology Platform.